Correlation Between Athira Pharma and Viking Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Athira Pharma and Viking Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Athira Pharma and Viking Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Athira Pharma and Viking Therapeutics, you can compare the effects of market volatilities on Athira Pharma and Viking Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Athira Pharma with a short position of Viking Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Athira Pharma and Viking Therapeutics.

Diversification Opportunities for Athira Pharma and Viking Therapeutics

0.88
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Athira and Viking is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Athira Pharma and Viking Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viking Therapeutics and Athira Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Athira Pharma are associated (or correlated) with Viking Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viking Therapeutics has no effect on the direction of Athira Pharma i.e., Athira Pharma and Viking Therapeutics go up and down completely randomly.

Pair Corralation between Athira Pharma and Viking Therapeutics

Given the investment horizon of 90 days Athira Pharma is expected to generate 0.92 times more return on investment than Viking Therapeutics. However, Athira Pharma is 1.08 times less risky than Viking Therapeutics. It trades about -0.13 of its potential returns per unit of risk. Viking Therapeutics is currently generating about -0.2 per unit of risk. If you would invest  66.00  in Athira Pharma on November 28, 2024 and sell it today you would lose (21.50) from holding Athira Pharma or give up 32.58% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Athira Pharma  vs.  Viking Therapeutics

 Performance 
       Timeline  
Athira Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Athira Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Viking Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Viking Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Athira Pharma and Viking Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Athira Pharma and Viking Therapeutics

The main advantage of trading using opposite Athira Pharma and Viking Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Athira Pharma position performs unexpectedly, Viking Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viking Therapeutics will offset losses from the drop in Viking Therapeutics' long position.
The idea behind Athira Pharma and Viking Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences